Benoxacor

Synonyms: CGA 154281
Benoxacor (CGA 154281) 是一种除草剂安全剂和外源物代谢调节剂,主要通过诱导 Glutathione S-transferase 等解毒酶来保护玉米免受异丙甲草胺的毒害,同时可激活 FXR、PXR 及 ERRα 并抑制芳香酶 (aromatase),但在动物模型中表现出潜在的亚急性口服毒性和较高的肝脏毒性风险,可诱导活性氧积累、干扰胚胎心脏发育,并导致小鼠肝肾重量增加及肠道菌群改变,因此可用于肝脂肪变性、不育症、乳腺癌及发育毒性相关研究。
产品编号: MS-P86916 纯度: 99.39% CAS No.: 98730-04-2 分子式: C11H11Cl2NO2 分子量: 260.12
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

Benoxacor (CGA 154281) 是一种除草剂安全剂和外源物代谢调节剂,主要通过诱导 Glutathione S-transferase 等解毒酶来保护玉米免受异丙甲草胺的毒害,同时可激活 FXR、PXR 及 ERRα 并抑制芳香酶 (aromatase),但在动物模型中表现出潜在的亚急性口服毒性和较高的肝脏毒性风险,可诱导活性氧积累、干扰胚胎心脏发育,并导致小鼠肝肾重量增加及肠道菌群改变,因此可用于肝脂肪变性、不育症、乳腺癌及发育毒性相关研究。

生物实验数据

生物活性 Benoxacor (CGA 154281) is a herbicide safener and xenobiotic metabolism modulator that primarily protects maize from metolachlor toxicity by inducing detoxifying enzymes such as Glutathione S-transferase, while also activating FXR, PXR, and ERRα and inhibiting aromatase; however, it exhibits potential subacute oral toxicity and a relatively high risk of hepatotoxicity in animal models, can induce reactive oxygen species accumulation, interfere with embryonic heart development, and cause increased liver and kidney weights and altered gut microbiota in mice, and is therefore applicable to research on hepatic steatosis, infertility, breast cancer, and developmental toxicity.
IC50 & Target

ERRα

 

体外研究
(In Vitro)

Benoxacor (5 μM; 0-30 min) 可被雄性 C57BL/6 小鼠肝微粒体以时间依赖性和对映体选择性方式代谢,其中细胞色素 P450 酶主要代谢 E2-benoxacor 对映体,微粒体羧酸酯酶主要代谢 E1-benoxacor 对映体;微粒体 CYP 清除的内在清除率为 1.05 mL/min/mg protein,标化清除率为 40.22 mL/min/g liver,而微粒体 CES 清除的内在清除率为 0.54 mL/min/mg protein,标化清除率为 20.77 mL/min/g liver。
Benoxacor (5 μM; 0-30 min) 可经谷胱甘肽 S-转移酶以时间依赖性和对映选择性方式被雄性 C57BL/6 小鼠肝脏胞液代谢,其中 GST 清除的固有清除率为 1.46 mL/min/mg protein,标化清除率为 132.52 mL/min/g liver。
Benoxacor (10 μM; 0.25-48 h) 可被玉米 (栽培品种:Black Mexican Sweet,下同) 悬浮培养细胞快速摄取,经 10 μM 处理后,摄取量在 48 h 内持续增加。
Benoxacor (10 μM; 0-48 h) 处理处理玉米悬浮培养细胞可使 GST-M 活性提升至两倍,该变化在处理后 4 h 即可检测到,24 h 时达到峰值。
Benoxacor (10 μM; 24 h) 可提高处理玉米悬浮培养细胞中经阴离子交换色谱分离得到的三种不同 GST 活性 (a、c、d)。
Benoxacor (10 μM; 24 h) 处理玉米悬浮培养细胞的分离 GST 组分 (b、c、d),可与玉米 GST I 及 GST I/III 抗血清发生交叉反应的 GST 多肽 (26,000-27,000 Mr),该模式与苯草酮处理的玉米幼苗中观察到的模式一致。
Benoxacor (10 μM; 24 h) 处理玉米悬浮培养细胞可使 GST-M 活性提升 3 倍,该效应会被 Cycloheximide (MS-C76056) (10/100 μM; 2 h) 预处理部分阻断,表明该诱导活性需要从头合成蛋白质。
Benoxacor (10 μM; 24 h) 处理处理玉米悬浮培养细胞可使 GST-M 活性提升 3 倍,而该提升作用可被 Cordycepin (MS-F48889) (10/100 μM; 2 h) 预处理大幅阻断,表明该诱导活性需要从头合成 RNA。

Western Blot Analysis

Cell Line: Zea mays (cv. Black Mexican Sweet) suspension-cultured cells
Concentration: 10 μM
Incubation Time: 24 h
Result: Detected a 27,000 Mr polypeptide in fractions corresponding to activities b and c with maize GST I antisera.
Detected a 27,000 Mr polypeptide in fraction corresponding to activity b, and a 27,000 Mr plus a slightly reactive 26,000 Mr polypeptide in fraction corresponding to activity c with maize GST I/III antisera.
Detected a slightly reactive 26,000 Mr polypeptide in fraction corresponding to activity d with maize GST I/III antisera.
体内研究
(In Vivo)

Benoxacor (0.5-50 mg/kg b.w.;灌胃;每日;连续 3 天) 对雄性 C57BL/6J 小鼠的亚急性经口暴露。50 mg/kg 可导致经体重校正后的肝脏和睾丸重量出现显著的剂量依赖性升高,同时会引起肝脏基因表达、代谢组学和肠道细菌属丰度发生轻微的、校正后无统计学意义的改变,但对肝脏抗氧化酶活性无影响。
Benoxacor (0.5-2.0 mg/L;水体暴露;持续暴露;5.5 至 72 hpf) 会在斑马鱼胚胎中引发浓度依赖性发育毒性、心脏形态与功能异常、氧化应激,以及细胞凋亡和心脏发育相关基因的表达失调,其中 2.0 mg/L 剂量产生的效应最为严重。

Animal Model: C57BL/6J mice (male, 8-week-old, acclimated for 4 weeks from 4-week-old)
Dosage: 0.5 mg/kg b.w.; 5 mg/kg b.w.; 50 mg/kg b.w.
Administration: p.o.; daily; 3 consecutive days
Result: Increased bodyweight-adjusted liver/testes weight significantly at 50 mg/kg.
Caused no significant changes in body weight or bodyweight-adjusted spleen, kidney, or brain weights at any dose.
Induced no overt pathological changes in liver or intestinal tissues at any dose.
Caused no significant effects on cecal microbiome α-diversity (Shannon, Chao-1 indices) or β-diversity (Weighted Unifrac distance) at any dose.
Identified 163 hepatic differentially expressed genes (DEGs) across all doses, including xenobiotic processing genes Cyp7a1, Cyp3a13, and Cyp26a1; the gene regulation profile matched that of dichloroacetic acid and sedaxane, with 15/16 and 15/21 consistent DE targets respectively, though this was not significant after multiple comparison correction.
Altered 9 serum and 15 liver metabolites before multiple comparison correction; in liver, creatinine and trigonelline were significantly altered, but no changes remained significant after false discovery rate correction.
Caused no significant changes in hepatic catalase, glutathione peroxidase (GPx), superoxide dismutase (SOD), or glutathione S-transferase (GST) activity at any dose.
Animal Model: wild-type AB; transgenic Tg Zebrafish (myl7:GFP) (embryos, exposed at 5.5 hours post-fertilization)
Dosage: 0.5 mg/L; 1.0 mg/L; 2.0 mg/L
Administration: aqueous exposure; continuous; 5.5 to 72 hpf
Result: Increased total mortality rate in a concentration-dependent manner, reaching ~13% at 72 hpf for the 2.0 mg/L dose, ~10% for the 1.0 mg/L dose, and ~6% for the 0.5 mg/L dose.
Reduced heart rate significantly in a concentration-dependent manner, with the 2.0 mg/L dose causing the greatest reduction relative to controls.
Reduced hatching rate significantly in a concentration-dependent manner at both 48 and 72 hpf, with the 2.0 mg/L dose resulting in the lowest hatching rate (~40%) at 72 hpf.
Induced pericardial edema and linear stretching of the heart, with failure of heart cyclization observed in all treated groups; revealed abnormalities in the myocardial layer and linearized atria/ventricles via histological analysis.
Increased ROS fluorescence intensity significantly in a concentration-dependent manner, with the 2.0 mg/L dose showing the highest intensity (~65,000 fluorescence units).
Elevated SOD and CAT activities in a concentration-dependent manner.
Decreased MDA content at 0.5 mg/L and 1.0 mg/L, then significantly increased it at 2.0 mg/L (~3.5 nmol/mL).
Upregulated relative mRNA levels of pro-apoptotic gene caspase 3 (peak ~3.2-fold at 1.0 mg/L) and cardiac development-related genes nkx2.5, myh6, tbx5a, vmhc, and nppa.
Downregulated relative mRNA levels of gata4 and tbx2b in a concentration-dependent manner, with caspase 9 showing a slight concentration-dependent decrease.
性状 固体
颜色 White to off-white

化学信息

分子量 260.12
分子式 C11H11Cl2NO2
CAS No. 98730-04-2
别名 CGA 154281

储存&溶解度

储存方式

4°C, stored under nitrogen

*In solvent: -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 125 mg/mL (480.55 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM3.8444 mL19.2219 mL38.4438 mL96.1095 mL
5 mM0.7689 mL3.8444 mL7.6888 mL19.2219 mL
10 mM0.3844 mL1.9222 mL3.8444 mL9.6109 mL
15 mM0.2563 mL1.2815 mL2.5629 mL6.4073 mL
20 mM0.1922 mL0.9611 mL1.9222 mL4.8055 mL
25 mM0.1538 mL0.7689 mL1.5378 mL3.8444 mL
30 mM0.1281 mL0.6407 mL1.2815 mL3.2036 mL
40 mM0.0961 mL0.4805 mL0.9611 mL2.4027 mL
50 mM0.0769 mL0.3844 mL0.7689 mL1.9222 mL
60 mM0.0641 mL0.3204 mL0.6407 mL1.6018 mL
80 mM0.0481 mL0.2403 mL0.4805 mL1.2014 mL
100 mM0.0384 mL0.1922 mL0.3844 mL0.9611 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (stored under nitrogen)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础